欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号DE/V/0323/001
药品名称Spasmalgan compositum
活性成分
    • metamizole sodium monohydrate 500.0 mg/ml
    • SCOPOLAMINE butylbromide 4.0 mg/ml
剂型Solution for injection
上市许可持有人Veyx-Pharma GmbH Söhrenweg 6 D-34639 Schwarzenborn Germany
参考成员国 - 产品名称Germany (DE)
互认成员国 - 产品名称
    • Luxembourg (LU)
    • Ireland (IE)
    • Austria (AT)
      Spasmalgan compositum 500 mg/ml + 4 mg/ml Injektionslösung für Pferde, Rinder, Schweine und Hunde
    • Spain (ES)
    • Portugal (PT)
    • Italy (IT)
    • Greece (GR)
    • Poland (PL)
    • Latvia (LV)
      Spasmalgan compositum 500 mg/ml + 4 mg/ml šķīdums injekcijām zirgiem, liellopiem, cūkām un suņiem
    • Lithuania (LT)
      Spasmalgan compositum 500 mg/ml + 4 mg/ml, injekcinis tirpalas arkliams, gavijams, kiaulėms ir šunims
    • Estonia (EE)
      Spasmalgan compositum
    • Hungary (HU)
    • Bulgaria (BG)
    • Cyprus (CY)
    • Czechia (CZ)
      Spasmalgan compositum 500 mg/ml + 4 mg/ml injekční roztok pro koně, skot, prasata, psy
    • Romania (RO)
    • Slovakia (SK)
    • Malta (MT)
    • Croatia (HR)
许可日期2020/04/01
最近更新日期2021/09/14
药物ATC编码
    • QA03DB04 butylscopolamine and analgesics
申请类型
  • TypeLevel1:food
  • TypeLevel2:Pharmaceutical
  • TypeLevel3:Generic - art 13.2 Dir 2001/82/EC
  • TypeLevel4:[not specified]
  • TypeLevel5:[not specified]
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase